CO6531435A2 - Nuevas formulaciones de vacuna que comprende adyuvantes que contienen saponina - Google Patents

Nuevas formulaciones de vacuna que comprende adyuvantes que contienen saponina

Info

Publication number
CO6531435A2
CO6531435A2 CO12058153A CO12058153A CO6531435A2 CO 6531435 A2 CO6531435 A2 CO 6531435A2 CO 12058153 A CO12058153 A CO 12058153A CO 12058153 A CO12058153 A CO 12058153A CO 6531435 A2 CO6531435 A2 CO 6531435A2
Authority
CO
Colombia
Prior art keywords
saponina
vaccine
new formulations
adjuvants containing
emulsion
Prior art date
Application number
CO12058153A
Other languages
English (en)
Inventor
Noel Joseph Francois Detraz
Guillaume Rigaut
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of CO6531435A2 publication Critical patent/CO6531435A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona una emulsión de aceite en agua (O/W) novedosa, con estabilidad incrementada en la presencia de suspensiones bacterianas o virales, especialmente aquellas concentradas y no purificadas (extractos crudos) o mínimamente purificadas. La emulsión de la presente invención puede actuar como vehículo para el suministro de una composición farmacéutica que comprende por lo menos un inmunógeno y, en particular, un inmunógeno seleccionado del grupo que consiste de un patógeno inactivado, un patógeno atenuado, una subunidad, un vector de expresión recombinante y un plásmido o combinaciones de los mismos.
CO12058153A 2009-09-10 2012-04-10 Nuevas formulaciones de vacuna que comprende adyuvantes que contienen saponina CO6531435A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24117109P 2009-09-10 2009-09-10

Publications (1)

Publication Number Publication Date
CO6531435A2 true CO6531435A2 (es) 2012-09-28

Family

ID=43063042

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12058153A CO6531435A2 (es) 2009-09-10 2012-04-10 Nuevas formulaciones de vacuna que comprende adyuvantes que contienen saponina

Country Status (28)

Country Link
US (2) US9107859B2 (es)
EP (1) EP2475384B1 (es)
JP (1) JP5759463B2 (es)
KR (1) KR101746880B1 (es)
CN (2) CN102573900B (es)
AR (2) AR078169A1 (es)
AU (1) AU2010292233B2 (es)
BR (1) BR112012005518B1 (es)
CA (1) CA2773486C (es)
CO (1) CO6531435A2 (es)
CY (1) CY1119052T1 (es)
DK (1) DK2475384T3 (es)
ES (1) ES2600929T3 (es)
HR (1) HRP20161414T1 (es)
HU (1) HUE030664T2 (es)
LT (1) LT2475384T (es)
MX (2) MX2012002814A (es)
MY (1) MY157607A (es)
NZ (1) NZ598645A (es)
PH (1) PH12012500477A1 (es)
PL (1) PL2475384T3 (es)
PT (1) PT2475384T (es)
RU (1) RU2555342C2 (es)
SG (1) SG179037A1 (es)
SI (1) SI2475384T1 (es)
SM (1) SMT201600394B (es)
UA (1) UA107940C2 (es)
WO (1) WO2011031850A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132932A1 (en) * 2009-05-19 2010-11-25 Bioproperties Pty Ltd A temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof
CN102648003B (zh) * 2009-10-09 2016-01-13 儿童医疗中心有限公司 选择性裂解的全细胞疫苗
CN102226153B (zh) * 2011-05-10 2012-12-05 黑龙江大学 用于生成污染菌抗血清的免疫原的制备方法
WO2013001034A1 (en) * 2011-06-28 2013-01-03 Leukocare Ag Novel stabilisation method for viruses or bacteria
SI2814508T1 (sl) 2012-02-14 2017-10-30 Merial, Inc. Rotavirusna podenotska cepiva ter postopki njihove izdelave in uporaba
RU2521513C1 (ru) * 2013-04-09 2014-06-27 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Применение этония в качестве адъюванта для производства сорбированной противоящурной вакцины
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
US9713639B2 (en) 2014-05-19 2017-07-25 Merial, Inc. Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (PEDV)
CN115317600A (zh) * 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
CN104803850A (zh) * 2015-04-29 2015-07-29 天津大学 一种酯类糖基相选择性亲油凝胶因子及其制备方法以及在油品胶凝中的应用
KR20180021816A (ko) 2015-06-26 2018-03-05 메리얼 인코포레이티드 불활성화된 개 인플루엔자 백신 및 이의 제조 방법 및 용도
WO2017062460A1 (en) 2015-10-08 2017-04-13 Merial, Inc. Live attenuated heterologous vaccine for leptospira
DK3380119T3 (da) 2015-11-23 2021-11-15 Boehringer Ingelheim Animal Health Usa Inc Fmdv- og e2-fusionsproteiner og anvendelser deraf
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
EP3439690A2 (en) 2016-04-07 2019-02-13 Merial, Inc. Heartworm vaccine, methods and uses thereof
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
CN117357641A (zh) 2016-12-14 2024-01-09 勃林格殷格翰动物保健美国公司 表达禽病原体的多种抗原的重组hvt载体及其用途
AU2018275672A1 (en) 2017-05-31 2020-01-16 Texas Tech University System Methods and devices for the treatment of food allergies
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN109806391A (zh) * 2017-11-22 2019-05-28 西北民族大学 一种兽用疫苗免疫水溶性复合佐剂的制备方法及其应用
CN108853493A (zh) * 2018-07-26 2018-11-23 中国人民解放军陆军军医大学 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用
CN111658611B (zh) * 2020-04-13 2021-06-01 四川大学 一种基于微乳的疫苗递送系统及其制备方法和应用
BR102021012953A2 (pt) * 2021-06-29 2023-01-10 Fabp Biotech Desenvolvimento Em Biotecnologia Ltda. Composição de vacina veterinária contra helmintos, método para tratamento e prevenção de infecção causada por helmintos e uso
US12036318B2 (en) * 2022-02-16 2024-07-16 Chemical & Schutz High Performance Lubricants, S.A. De C.V. Self-emulsionable mineral oil as a vehicle in vaccines for poultry
CN117281899B (zh) * 2022-06-24 2024-09-17 江苏瑞科生物技术股份有限公司 一种佐剂系统及其制备方法和应用
CN116983396B (zh) * 2023-08-09 2024-05-07 浙江省农业科学院 兔支气管败血波氏杆菌灭活疫苗乳剂及其制备和应用
CN119656300A (zh) * 2024-12-17 2025-03-21 长江大学 一种猪繁殖与呼吸综合征灭活苗专用油佐剂及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2777608A (en) 1953-09-18 1957-01-15 Sheffler James Soap powder dispenser attachment
GB1143545A (en) * 1965-03-25 1969-02-26 Wellcome Found Injectable vaccine emulsions
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
CA2082155C (en) 1990-05-29 2008-04-15 Krishnaswamy I. Dayalu Swine pneumonia vaccine and method of preparation
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
JP3723231B2 (ja) * 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
KR100374295B1 (ko) 1993-02-08 2003-12-24 바이엘 코포레이션 돼지생식및호흡증후군바이러스의생육방법과백신에서그의용도
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5997881A (en) 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
CA2302522C (en) * 1997-08-29 2010-08-17 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
AU1145699A (en) * 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
NZ508013A (en) 1998-05-07 2003-08-29 Corixa Corp Adjuvant composition for use with an antigen in a vaccine composition
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
CA2290220C (en) * 1998-12-22 2013-11-19 Pfizer Products Inc. An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
GB0009735D0 (en) * 2000-04-19 2000-06-07 Zeneca Ltd Formulation
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
DE10113284A1 (de) 2001-03-16 2002-10-02 Heinrich Exner Adjuvans-Emulsion und Verfahren zu deren Verwendung
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US6642178B2 (en) * 2001-11-14 2003-11-04 North Dakota State University Adjuvant blend for enhancing efficacy of pesticides
US7378101B2 (en) * 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
US7371395B2 (en) * 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
EP1968630B1 (en) * 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
JP2010512748A (ja) * 2006-12-15 2010-04-30 シェーリング−プラウ・リミテッド インフルエンザウイルスを培養物中で複製するための方法

Also Published As

Publication number Publication date
CA2773486A1 (en) 2011-03-17
DK2475384T3 (en) 2016-10-24
MX2012002814A (es) 2012-08-17
KR101746880B1 (ko) 2017-06-14
CN107213461A (zh) 2017-09-29
CA2773486C (en) 2017-10-10
AU2010292233A1 (en) 2012-04-05
AU2010292233B2 (en) 2014-03-06
CN102573900B (zh) 2017-05-31
SG179037A1 (en) 2012-04-27
NZ598645A (en) 2014-07-25
PL2475384T3 (pl) 2017-02-28
MX344863B (es) 2017-01-10
PH12012500477A1 (en) 2012-10-22
CY1119052T1 (el) 2018-01-10
UA107940C2 (en) 2015-03-10
US9730987B2 (en) 2017-08-15
AR078169A1 (es) 2011-10-19
HRP20161414T1 (hr) 2016-12-02
LT2475384T (lt) 2016-11-25
BR112012005518A2 (pt) 2017-09-05
JP2013504583A (ja) 2013-02-07
ES2600929T3 (es) 2017-02-13
US9107859B2 (en) 2015-08-18
CN107213461B (zh) 2022-03-15
MY157607A (en) 2016-06-30
EP2475384B1 (en) 2016-08-10
RU2012113814A (ru) 2013-10-20
HUE030664T2 (en) 2017-05-29
US20110129494A1 (en) 2011-06-02
PT2475384T (pt) 2016-11-17
KR20120108968A (ko) 2012-10-05
SI2475384T1 (sl) 2016-12-30
CN102573900A (zh) 2012-07-11
AR121096A2 (es) 2022-04-20
JP5759463B2 (ja) 2015-08-05
EP2475384A1 (en) 2012-07-18
SMT201600394B (it) 2017-01-10
RU2555342C2 (ru) 2015-07-10
WO2011031850A1 (en) 2011-03-17
BR112012005518B1 (pt) 2021-11-30
US20150196487A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
CO6531435A2 (es) Nuevas formulaciones de vacuna que comprende adyuvantes que contienen saponina
CO2023001072A2 (es) Vacuna combinada de sars-cov-2 e influenza
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
AR133161A2 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
EP4691484A3 (en) Influenza mrna vaccines
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
MX347210B (es) Vacunas combinadas para prevención de infecciones por virus porcino.
MA40765B1 (fr) Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
AR061894A1 (es) Vacunas para malaria
EA201391515A1 (ru) Инактивированная вакцина вируса денге
PE20200336A1 (es) Formulaciones a largo plazo
MX363464B (es) Vacunas contra influenza h5.
MX360206B (es) Compuestos inmunogenicos que comprenden peptido de proteina transmembrana 41 (gp41) del virus de inmunodeficiencia humana (vih) acoplado a proteina transportadora crm197.
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
AR073907A1 (es) Adyuvante para vacunas, que comprende un polipeptido no lipidado de la membrana externa (omp) de bacterias, vacunas que lo comprenden y usos
MX420767B (es) Proteina de union al factor h modificada
ZA202104747B (en) Novel trypanosomal vaccine
MX2017002949A (es) Arbovirus recodificado y vacunas.